The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
Open accessThe DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function, while the inhibition of α-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Ten male patients with well-regulated type 2 diabetes (A1C 6.9 ± 0.8%, age 56 ± 10 years, BMI 31 ± 3 kg/m2 [means ± SD]) were subjected to five 120-min glucose clamps at fasting plasma glucose (FPG) levels. On day 1, GLP-1 was infused to stimulate endogenous insulin release and suppress endogenous glucagon. On days 2–5, pancreatic endocrine clamps were performed using somatostatin infusions of somatostatin and/or selective replacement of insulin and glucagon; day 2, GLP-1 plus basal insulin and glucagon (no glucagon suppression or insulin stimulation); day 3, basal insulin only (glucagon deficiency); day 4, basal glucagon and stimulated insulin; and day 5, stimulated insulin. The basal plasma glucagon levels were chosen to simulate portal glucagon levels. RESULTS: Peptide infusions produced the desired hormone levels. The amount of glucose required to clamp FPG was 24.5 ± 4.1 (day 1), 0.3 ± 0.2 (day 2), 10.6 ± 1.1 (day 3), 11.5 ± 2.7 (day 4), and 24.5 ± 2.6 g (day 5) (day 2 was lower than days 3 and 4, which were both similar and lower than days 1 and 5). CONCLUSIONS: We concluded that insulin stimulation (day 4) and glucagon inhibition (day 3) contribute equally to the effect of GLP-1 on glucose turnover in patients with type 2 diabetes, and these changes explain the glucose-lowering effect of GLP-1 (day 5 vs. day 1).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Considering the prominent role of adipose tissue in energy homeostasis59,172, it is plausible that GIPR agonism in fat could harness beneficial effects on metabolic homeostasis.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [59]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 2×
“We employed the pancreatic clamp technique (11) using somatostatin to block the endogenous secretion from the islets while substituting insulin and/or glucagon levels by infusions designed to mimic either basal levels and/or responses to a GLP-1 infusion rate (1 pmol/kg/min) known to normalize blood glucose in patient…”
BackgroundMethodSelf-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“The assay reacts equally with intact GLP-1 and with GLP-1 (9–36) amide, the primary metabolite (16).”
MethodSelf-citationGlucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905 · cited 1×
“Since in humans the target of glucagon action is the liver (18,19), which is exposed to portal glucagon levels, we chose the portal levels; these were successfully reached (in peripheral plasma) during the glucagon infusions.”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 1×
“Despite their hyperglycemia, patients with type 2 diabetes tend to have elevated fasting glucagon levels and exaggerated glucagon responses to meal ingestion (5).”
BackgroundSelf-citation共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Clamp studies in patients with type 2 diabetes indicate that GLP-1 inhibition of glucagon secretion is equally important for lowering blood glucose as GLP-1 stimulation of insulin release [578].”
BackgroundSelf-citationGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialGIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“Clinical studies have indicated that GLP-1-induced inhibition of glucagon secretion contributes significantly to the glucose-lowering capacity of GLP-1-based therapies and may be as important as their insulinotropic effects [26].”
BackgroundThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“Under in vivo conditions, however, GLP-1 inhibits glucagon secretion (120, 262, 331, 496) and inhibition of GLP-1 action through infusion of the GLP-1 antagonist exendin(9–39)amide (528) increases glucagon secretion in humans (as also reviewed in Refs.”
BackgroundGilbert, M. P., & Pratley, R. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00178 · Cited by 407
Nauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251
“GLP-1 acts as a glucose-dependent stimulator of pancreatic insulin secretion and at the same time it glucose-dependently inhibits pancreatic glucagon secretion [5].”
Self-citationHjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245
“suppress glucagon and slow gastric emptying, which affects the postprandial glucose response.(13,14,19) The observed reduction in postprandial insulin and C-peptide in this trial may be explained, in part, by the reduction in glucose concentrations observed after 12 weeks of treatment.”
BackgroundThe role of dysregulated glucagon secretion in type 2 diabetes
D'Alessio, D. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01449.x · Cited by 238
“Moreover, recent work using somatostatin to block islet hormone release and exogenous infusions to match the levels seen after GLP-1 administration suggests that the effects of glucagon lowering and insulin stimulation are roughly equivalent to maintain fasting glucose [60].”
BackgroundMechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss
Holst, J. J., Madsbad, S., Bojsen-Møller, K. N., Svane, M. S., Jørgensen, N. B., Dirksen, C., & Martinussen, C. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.03.003 · Cited by 202
Self-citationUmapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193
“Acute administration of glucagon-like peptide 1 (GLP1) to healthy humans, and patients with type 2 diabetes, lowers blood glucose concentrations by stimulating insulin, suppressing glucagon secretion, and slowing gastric emptying (1).”
BackgroundKapitza, C., Forst, T., Coester, H. ‐., Poitiers, F., Ruus, P., & Hincelin‐Méry, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12076 · Cited by 191
“Insulin secretion was decreased with lixisenatide and relatively unchanged with liraglutide, but this needs to be considered in the context of markedly lower PPG levels with lixisenatide, and these observations would be consistent with glucose-dependent insulinotropic effects and previous observations with exenatide […”
ResultIncretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
The role of diet and intestinal microbiota in the development of metabolic syndrome
Santos-Marcos, J. A., Perez-Jimenez, F., & Camargo, A. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.03.017 · Cited by 180
Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond
Cho, Y. M., Fujita, Y., & Kieffer, T. J. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170315 · Cited by 174
“A pancreatic endocrine clamp experiment in patients with well-controlled type 2 diabetes revealed that the glucagonostatic action of GLP-1 is perhaps as important as its insulinotropic action in lowering glucose (92).”
BackgroundBahne, E., Sun, E. W. L., Young, R. L., Hansen, M., Sonne, D. P., Hansen, J. S., Rohde, U., Liou, A. P., Jackson, M. L., de Fontgalland, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.93936 · Cited by 173
Self-citationGlucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Self-citationSSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells
Kailey, B., van de Bunt, M., Cheley, S., Johnson, P. R., MacDonald, P. E., Gloyn, A. L., Rorsman, P., & Braun, M. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00207.2012 · Cited by 164
“Reducing glucagon secretion can improve glucose homeostasis in diabetes and is therefore therapeutically desirable (18).”
BackgroundThe Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
“In patients with T2D, the glucagonsuppressive effect of GLP-1RAs likely contributes approximately one-third of the overall glucoselowering effect.(50,185) Decreased glucagon levels with GLP-1RA treatment result in an increased insulin:glucagon ratio.”
BackgroundSelf-citationComparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Golightly, L. K., Drayna, C. C., & McDermott, M. T. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261927 · Cited by 158
“Further, it has been shown that inhibition of glucagon secretion and stimulation of insulin secretion contribute equally to these glucoselowering actions.([11]) When considered in light of several novel ancillary pharmacological actions of various incretin treatments that may be of additional therapeutic benefit,([12-…”
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases
Hædersdal, S., Andersen, A., Knop, F. K., & Vilsbøll, T. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00817-4 · Cited by 176
Self-citationPharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Holst, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00260 · Cited by 147
Self-citationRecent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
“Clamp studies in patients with T2D indicate that the insulinotropic and glucagonostatic effects of GLP-1 contribute equally to decreasing blood glucose (75).”
BackgroundThe intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
“GIP stimulates glucagon secretion 81 , whereas GLP1 suppresses secretion; evidence suggests that the opposite effects of GLP1 on insulin and glucagon secretion both contribute to lowering of plasma glucose 82 .”
BackgroundRegulation of glucagon secretion by incretins
Holst, J. J., Christensen, M., Lund, A., de Heer, J., Svendsen, B., Kielgast, U., & Knop, F. K. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01452.x · Cited by 144
“In a recent study [53], the clinical importance of the inhibitory effect of GLP-1 on glucagon secretion was examined.”
BackgroundSelf-citationTargeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
Pan, Q., Lin, S., Li, Y., Liu, L., Li, X., Gao, X., Yan, J., Gu, B., Chen, X., Li, W., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2020.103202 · Cited by 139
Brunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Ramracheya, R., Chapman, C., Chibalina, M., Dou, H., Miranda, C., González, A., Moritoh, Y., Shigeto, M., Zhang, Q., Braun, M., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13852 · Cited by 128
“GLP-1 infusions in nondiabetic men have demonstrated that the plasma glucose-lowering action of GLP-1 is due to both a reduction in glucagon and increase in insulin secretion (Hare et al. 2010).”
BackgroundMolecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells
Leech, C. A., Dzhura, I., Chepurny, O. G., Kang, G., Schwede, F., Genieser, H.-G., & Holz, G. G. (2011) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2011.07.005 · Cited by 128
“Administered GLP-1R analogs act at pancreatic a cells to inhibit glucagon secretion, and this effect is accompanied by a suppression of hepatic glucose production (Hare et al., 2010).”
BackgroundThe Biology of Glucagon and the Consequences of Hyperglucagonemia
Wewer Albrechtsen, N. J., Kuhre, R. E., Pedersen, J., Knop, F. K., & Holst, J. J. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0090 · Cited by 129
Self-citationPhysiology of Incretins in Health and Disease
Deacon, C. F., & Ahrén, B. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.293 · Cited by 126
“Both the stimulation of insulin and the suppression of glucagon secretion are important mediators, and have been demonstrated to contribute almost equally to the glucoselowering effect of GLP-1 [71].”
BackgroundSelf-citationGlucagon and Type 2 Diabetes: the Return of the Alpha Cell
Lund, A., Bagger, J. I., Christensen, M., Knop, F. K., & Vilsbøll, T. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0555-4 · Cited by 144
Self-citationGlucagon antagonism as a potential therapeutic target in type 2 diabetes
Bagger, J. I., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01427.x · Cited by 124
“Studies in humans with dipeptidyl peptidase (DPP)-4 inhibitors [29,30] as well as studies involving pancreatic clamping indicate that a considerable part of the glucose-lowering effect of GLP-1 is secondary to inhibition of glucagon secretion [31].”
BackgroundSelf-citationParker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz047 · Cited by 123
“Given the known impact of glucagon on GET and the differential effects of short- and longacting GLP-1 analogues (9,10), it is unclear whether such effects are mediated via GLP-1 or”
BackgroundTransforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Kapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B., & Flint, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4289-0 · Cited by 117
“In another study, liraglutide restored beta cell responsiveness to glucose during a stepwise glucose clamp [11], which is in line with trials showing glucose-dependent insulin secretion [12], decreased glucagon secretion from pancreatic islets [12, 13] and delayed gastric emptying [14, 15].”
Result100 years of glucagon and 100 more
Wewer Albrechtsen, N. J., Holst, J. J., Cherrington, A. D., Finan, B., Gluud, L. L., Dean, E. D., Campbell, J. E., Bloom, S. R., Tan, T. M.-M., Knop, F. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05947-y · Cited by 117
Self-citationGLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M. S., Cirincione, B. B., Maggs, D., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 113
Swithers, S. E., Laboy, A. F., Clark, K., Cooper, S., & Davidson, T. L. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.04.024 · Cited by 113
Glucagon secretion from pancreatic α-cells
Briant, L., Salehi, A., Vergari, E., Zhang, Q., & Rorsman, P. (2016) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2016.1156789 · Cited by 109
Godinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 109
“Furthermore, it has been recently reported that insulin stimulation and glucagon inhibition contribute equally to the effect of GLP-1 on glucose turnover in T2DM patients [37].”
BackgroundBilling, L. J., Larraufie, P., Lewis, J., Leiter, A., Li, J., Lam, B., Yeo, G. S., Goldspink, D. A., Kay, R. G., Gribble, F. M., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.001 · Cited by 107
Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
“It should also be pointed out that GLP1RAs derive a large part of their hypoglycaemic effects by suppressing native glucagon secretion 114 .”
The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
Ørgaard, A., & Holst, J. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4315-2 · Cited by 101
“glucose-lowering activity of GLP-1 [5].”
Self-citationGupta, V., & Kalra, S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.85583 · Cited by 95
“” [1,2,10-34] Gupta and Kalra: Choosing a Gliptin”
BackgroundOkamoto, H., Kim, J., Aglione, J., Lee, J., Cavino, K., Na, E., Rafique, A., Kim, J. H., Harp, J., Valenzuela, D. M., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1011 · Cited by 100
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes
Wu, T., Little, T. J., Bound, M. J., Borg, M., Zhang, X., Deacon, C. F., Horowitz, M., Jones, K. L., & Rayner, C. K. (2016) · Diabetes Care · doi:10.2337/dc15-2298 · Cited by 99
“sion of peptide YY[1-36] to [3-36]) (29),”
Self-citationThe role of glucagon on type 2 diabetes at a glance
Godoy-Matos, A. F. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-91 · Cited by 99
“[41] suggested that the effect of GLP-1 consists of the improvement of glucose-induced insulin secretion, resulting in rather unchanged absolute secretion rates, while glucagon secretion, which would have been expected to augment with falling glucose concentrations, actually reduces.”
BackgroundMuzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 125
Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis
Suppli, M. P., Bagger, J. I., Lund, A., Demant, M., van Hall, G., Strandberg, C., Kønig, M. J., Rigbolt, K., Langhoff, J. L., Wewer Albrechtsen, N. J., et al. (2020) · Diabetes · doi:10.2337/db19-0715 · Cited by 95
Self-citationRorsman, P., Ramracheya, R. D., Rorsman, N. J. G., & Zhang, Q. (2014) · Diabetologia · doi:10.1007/s00125-014-3279-8 · Cited by 100
“The capacity of glucagon-like peptide 1 (GLP-1) to inhibit glucagon secretion [63] has also been attributed to an intrinsic mechanism (but see [64] for an alternative paracrine viewpoint) that culminates in reduced activation of alpha cell P/Qtype Ca channels [65].”
BackgroundGlucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Self-citationThe Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes
Gilon, P. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.004 · Cited by 92
de Azevedo, F. R., Santoro, S., Corrêa‐Giannella, M. L., Toyoshima, M. T. K., Giannella‐Neto, D., Calderaro, D., Gualandro, D. M., Yu, P. C., & Caramelli, B. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3239-3 · Cited by 97
“GLP1, in contrast to GIP, lowers glucagon secretion, decreasing glucose levels [13, 14].”
BackgroundObesity dysregulates fasting-induced changes in glucagon secretion
Stern, J. H., Smith, G. I., Chen, S., Unger, R. H., Klein, S., & Scherer, P. E. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0201 · Cited by 84
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
“The glucagonostatic effect of GLP-1 seems equally important as its insulinotropic action for the glucose-lowering effect of exogenous GLP-1 in patients with type 2 diabetes [79].”
BackgroundSelf-citationThe Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
“There is growing appreciation that a considerable portion of the glucose-lowering effect of GLP-1 is underscored by its inhibitory effect on gastric motility (80– 83) and its glucagonostatic action (84, 85), which are preserved in obese and T2D patients (86, 87).”
BackgroundBailey, T. S. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.009 · Cited by 84
“In addition to stimulating insulin release, GLP-1 has the additional benefit of suppressing glucagon secretion.(52,53) Because these endogenous peptides are released in response to nutrient ingestion, stimulation of insulin release occurs in proportion to the actual glucose load ingested, thus, there is negligible ris…”
BackgroundNicolaus, M., Brödl, J., Linke, R., Woerle, H.-J., Göke, B., & Schirra, J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0841 · Cited by 73
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
Self-citationGLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle
Sjøberg, K. A., Holst, J. J., Rattigan, S., Richter, E. A., & Kiens, B. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00283.2013 · Cited by 69
“This was necessary because GLP-1 infusions of 1 pmol·kg (1)·min 1 decrease hepatic glucose output in healthy male subjects (23) and in type 2 diabetic patients (20) due to the insulinotropic effect combined with decreasing plasma glucagon levels.”
BackgroundSelf-citationOligosaccharides Might Contribute to the Antidiabetic Effect of Honey: A Review of the Literature
Erejuwa, O. O., Sulaiman, S. A., & Wahab, M. S. A. (2011) · Molecules · doi:10.3390/molecules17010248 · Cited by 77
“They also exert a stimulatory role in pancreas resulting in enhanced insulin secretion and ß-cell proliferation, thus contributing to improved glucose disposal [92-95].”
BackgroundThe Alpha-Cell as Target for Type 2 Diabetes Therapy
Christensen, M., Bagger, J. I., Vilsboll, T., & Knop, F. K. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.369 · Cited by 65
Self-citationThe future of incretin‐based therapy: novel avenues—novel targets
Åhrén, B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01457.x · Cited by 63
“A recent study showed that the reduction in glucagon by GLP-1 accounts for approximately 50% of the reduction in glucose, that is, it is of similar importance as the stimulation of insulin secretion [69].”
BackgroundXie, C., Jones, K. L., Rayner, C. K., & Wu, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090790 · Cited by 67
“Within the pancreas, GLP-1 stimulates insulin secretion from the pancreatic β-cells and suppresses glucagon secretion from the α-cells in a glucose-dependent manner [52].”
BackgroundAlpha cell dysfunction in type 1 diabetes
Yosten, G. L. C. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.001 · Cited by 62
Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block
Moon, J. S., & Won, K. C. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.1.1 · Cited by 61
Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
Florentin, M., Kostapanos, M. S., & Papazafiropoulou, A. K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i2.85 · Cited by 75
Glucagon's Metabolic Action in Health and Disease
Zeigerer, A., Sekar, R., Kleinert, M., Nason, S., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive Physiology · doi:10.1002/cphy.c200013 · Cited by 59
“GLP-1 (60, 153, 184) and glucose-dependent insulinotropic polypeptide (GIP) (49, 96) both indirectly inhibit glucagon secretion, presumably via their ability to stimulate the secretion of insulin and Zn 2 + .”
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 68
Glucagon orchestrates stress‐induced hyperglycaemia
Harp, J. B., Yancopoulos, G. D., & Gromada, J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12668 · Cited by 61
“Dysregulated GLP-1 secretion or GLP-1 deficiency is not a well-defined feature of SIH, but∼50% of the glucose-lowering effect of GLP-1 receptor agonists, approved for the treatment of T2D, has been attributed to suppression of glucagon secretion, making this class of agents a plausible treatment option in patients wit…”
BackgroundGeloneze, B., Geloneze, S. R., Chaim, É. A., Hirsch, F. F., Felici, A. C., Lambert, G., Tambascia, M. A., & Pareja, J. C. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182592c62 · Cited by 65
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Kang, Z. F., Deng, Y., Zhou, Y., Fan, R. R., Chan, J. C. N., Laybutt, D. R., Luzuriaga, J., & Xu, G. (2013) · Diabetologia · doi:10.1007/s00125-012-2776-x · Cited by 54
“Moreover, a growing body of evidence has shown that the glucose-lowering effects of GLP-1 are mediated by various mechanisms, including stimulation of glucose-dependent insulin secretion in pancreatic beta cells [1, 2], promotion of pancreatic beta cell proliferation and inhibition of beta cell apoptosis [9–11], inhib…”
BackgroundZhang, X., Young, R. L., Bound, M., Hu, S., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2019) · Diabetes Care · doi:10.2337/dc18-2156 · Cited by 52
“Moreover, GLP-1 has a physiological role in slowing gastric emptying (6) and suppressing glucagon secretion (7) and energy intake (8).”
BackgroundRauch, T., Graefe-Mody, U., Deacon, C. F., Ring, A., Holst, J. J., Woerle, H.-J., Dugi, K. A., & Heise, T. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0010-y · Cited by 51
“The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.”
BackgroundInfluentialSelf-citationHamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 94
“In hyperglycemic situations, they also limit the release of glucagon from α -cells, which improves glucose homeostasis by reducing glucose synthesis in the liver [40,41].”
BackgroundJessen, L., Smith, E. P., Ulrich-Lai, Y., Herman, J. P., Seeley, R. J., Sandoval, D., & D’Alessio, D. (2017) · Endocrinology · doi:10.1210/en.2016-1826 · Cited by 48
Glucagon, from past to present: a century of intensive research and controversies
Scheen, A. J., & Lefèbvre, P. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00349-7 · Cited by 44
Inhibiting or antagonizing glucagon: making progress in diabetes care
Lefèbvre, P. J., Paquot, N., & Scheen, A. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12480 · Cited by 44
“[44] elegantly showed that inhibition of glucagon secretion and stimulation of insulin release contribute equally to its glucose-lowering action.”
BackgroundAn overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
“lowering effect of GLP-1 in patients with T2DM.[44] In addition, GLP-1 dose-dependently decreases gastrointestinal motility, which helps to prevent the rapid entry”
BackgroundInfluentialMetabolic Messengers: glucagon
MacDonald, P. E., & Rorsman, P. (2023) · Nature Metabolism · doi:10.1038/s42255-022-00725-3 · Cited by 43
GLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 45
Peptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2022) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 43
“Treatments with GLP-1 analogs and DPP-4 inhibitors (aimed at prolonging the half-life of released GLP-1), are both effective methods for treating T2D, both because of the glucose-dependent stimulation of insulin secretion (which means that hypoglycemia is avoided), but also because of the inhibitory actions on glucago…”
Self-citationFunctional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 42
Modvig, I. M., Andersen, D. B., Grunddal, K. V., Kuhre, R. E., Martinussen, C., Christiansen, C. B., Ørskov, C., Larraufie, P., Kay, R. G., Reimann, F. M., et al. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0541-7 · Cited by 44
“However, to our surprise, there was a short-lasting increase in glucagon secretion after secretin injection in vivo, which was uninfluenced by the glucagonostatic effect of GLP-1 [52] and sympathetic stress (as this was not observed in the control group), as observed when similar doses of both peptides were injected.”
Self-citationKatsuno, T., Ikeda, H., Ida, K., Miyagawa, J., & Namba, M. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej12-0293 · Cited by 40
Abdesselam, I., Pepino, P., Troalen, T., Macia, M., Ancel, P., Masi, B., Fourny, N., Gaborit, B., Giannesini, B., Kober, F., et al. (2015) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-015-0198-x · Cited by 42
Purnell, J. Q., Johnson, G., Wahed, A. S., Man, C. D., Piccinini, F., Cobelli, C., Prigeon, R. L., Goodpaster, B. H., Kelley, D. E., Staten, M. A., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4553-y · Cited by 43
“Counterintuitively, we found that despite large postsurgical weight loss and increases in peak insulin, glucose and GLP-1 levels [31, 32], the post-meal glucagon AUC did not change, and peak concentrations increased.”
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“Notably, studies in type-2 diabetic patients suggest that the insulinotropic and the glucagonostatic effects of GLP-1 contribute equally to its ability to decrease blood glucose [43].”
BackgroundChueire, V. B., & Muscelli, E. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000313 · Cited by 50
Cross Talk Between Insulin and Glucagon Receptor Signaling in the Hepatocyte
Habegger, K. M. (2022) · Diabetes · doi:10.2337/dbi22-0002 · Cited by 44
Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity
Opinto, G., Natalicchio, A., & Marchetti, P. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.812664 · Cited by 51
“Both the stimulation of insulin and the suppression of glucagon secretion are important mediators and have been demonstrated to contribute almost equally to the glucose lowering effect of GLP-1 (Hare et al., 2010).”
Background
Metadata
- Authors
- Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, Jens J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-07-01
- Volume
- 59
- Issue
- 7
- Pages
- 1765-1770
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2889777
- OpenAlex
- W2117402345
- Cited by
- 276
- References
- 34
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 17 · 2023: 19 · 2022: 13 · 2021: 18 · 2020: 20 · 2019: 24 · 2018: 13 · 2017: 15 · 2016: 19 · 2015: 20 · 2014: 20 · 2013: 19 · 2012: 16
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, type 2 diabetes, glucagon inhibition, insulin secretion, glucose-lowering effect, alpha cells, pancreatic beta cells, somatostatin, glucose turnover, insulin replacement therapy
- MeSH terms
- Insulin Secretion, Adult, Analysis of Variance, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Humans, Insulin, Male, Middle Aged, Time Factors, Glucose Clamp Technique, Treatment Outcome, Area Under Curve, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.